Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate, House Panels Release Clean Device User-Fee Discussion Draft

Executive Summary

Lawmakers emphasized the need for a swift reauthorization of a combined US FDA device and drug user-fee reauthorization bill before the end of July, and released a clean discussion draft April 14 that mirrors the agreements reached by industry and the agency last summer.

You may also be interested in...

Bill Bonanza: US Congress Sprouts Medtech Legislation This Spring

A bumper-crop of bipartisan-sponsored, mostly industry-supported legislation seeking to streamline compliance, improve access or otherwise reduce burdens in the medical device space has surfaced in recent months under the GOP-led Congress, just in time to potentially be considered in conjunction with "must-pass" user-fee reauthorization. The bills' targets range from hearing aids to diagnostics and from facility inspections to device repair services to Medicare reimbursement. Here's a roundup of introduced and draft legislation compiled by Medtech Insight.

Sen. Klobuchar Forming Coalition To Push For Both Device, Cadillac Tax Repeal

Sen. Amy Klobuchar, D-Minn., is putting together a coalition of lawmakers who favor repeal of both the medical device excise tax and the Affordable Care Act's so-called "Cadillac tax" on high-expense health-care plans.

Lab Professionals Oppose Draft Dx Reform Bill; Lab, IVD Industry Ready To Work With Congress

The clinical lab industry and IVD test-kit-makers appear ready to work with lawmakers on diagnostic reforms that would create a new category of regulated product for all lab tests that would undergo a mix of US FDA and CMS oversight. Meanwhile, key groups representing laboratory professionals remain fundamentally opposed to the concept.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts